Johnson & Johnson has exemplified shareholder commitment by increasing its dividend for more than 60 consecutive years. Its annual payout stands at $5.20 per share, translating to a yield of approximately 2.5%. Over the past decade, including dividend reinvestment, the company has delivered a total return of roughly 165%, underscoring the stock’s role as a reliable anchor for long-term, income-focused investors.

As one of only two U.S. corporates holding an AAA credit rating—surpassing even the U.S. government—Johnson & Johnson reported third-quarter sales of $24 billion, up 6.8% year-over-year despite patent expiry pressures on its Stelara franchise. The company’s gross margin exceeded 68%, and operating cash flow remains consistently strong, supporting ongoing R&D investments and dividend growth without elevating leverage.

By 2024, J&J ranked as the world’s third-largest oncology company, driven by top-selling therapies such as Darzalex, Carvykti and Erleada. Its Rybrevant–Lazcluze combination has become the new first-line standard for EGFR-mutated non-small cell lung cancer, with peak franchise revenues projected at $5 billion annually. Inlexzo, approved in September 2025 for BCG-unresponsive non-muscle invasive bladder cancer, offers a practice-changing, intravesical delivery system poised to replace surgical interventions. Beyond these, J&J sustains over 20 novel therapies in clinical development and anticipates 50 product expansions by 2030, positioning it for durable growth in high-margin specialty markets.